Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Zealand Pharma Reports Nine-Month Profit of DKK 3.47 Billion

By Public Technologies
  • Zealand Pharma reported nine-month 2026 profit of DKK 3.47 billion and revenue of DKK 4.53 billion.
  • Cash position fell 11% from December 31, 2025, to DKK 13.51 billion at September 30, 2026.
  • Petrelintide entered Phase 3 development with Roche, while Boehringer Ingelheim plans global obesity regulatory submissions for survodutide in 2027.
  • The 2026 revenue outlook remained unchanged at DKK 4.5 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120100PRIMZONEFULLFEED1001303125) on November 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.